| Tirzepatide | Semaglutide |
| Full UK regulatory approval specifically for managing weight (and people in England and Northern Ireland living with type 2 diabetes may be offered Mounjaro if they can’t access other GLP-1 medications) | Primarily approved for blood sugar control in type 2 diabetes patients, although weight loss is a prominent side effect. |
| In a study, Mounjaro led to weight loss of 17 lb to 25 lb on average across a 40-week trial | In the same study, Ozempic (1 mg dose) led to weight loss of 13 lb on average |
| Reduces appetite, delays stomach emptying and makes you feel fuller for longer | Regulates blood sugar levels by boosting insulin utilisation |
| Maximum dose of 15 mg | Maximum dose of 1 mg approved in the UK |
|